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http://dx.doi.org/10.1016/j.jacl.2016.02BACKGROUND: Apolipoprotein C-III (ApoC-III) regulates lipoprotein and triglyceride (TG) meta-
bolism and may have a causal role in cardiovascular disease. In the Multi-Center, Placebo-Controlled,
Randomized, Double-Blind, 12-Week Study With an Open-Label Extension (MARINE) and ANCHOR
studies, icosapent ethyl, a high-purity prescription eicosapentaenoic acid ethyl ester, reduced TG, and
other atherogenic lipid parameters without increasing low-density lipoprotein cholesterol (LDL-C)
compared with placebo.
OBJECTIVE: To evaluate the effects of icosapent ethyl on plasma ApoC-III levels in patients from
2 phase 3 studies.
METHODS: MARINE and ANCHOR were 12-week double-blind studies of icosapent ethyl in adult
patients. Patients in MARINE had very high TG levels ($500 and #2000 mg/dL) and patients in
ANCHORhadhighTG levels ($200 and,500mg/dL) despite statin control ofLDL-C.This post hoc anal-
ysis of MARINE and ANCHOR assessed the median percent change from baseline in plasma ApoC-III
levels vs placebo and includes subgroup analyses by statin use/efficacy and median ApoC-III levels.
RESULTS: WeassessedApoC-III levels in 148 and 612 patients in theMARINE andANCHORstudies,
respectively. InMARINE, the approved prescription dose of icosapent ethyl (4 g/day) significantly reduced
ApoC-III levels by 25.1% (P , .0001) vs placebo. In ANCHOR, icosapent ethyl 4 g/day significantly
reduced ApoC-III levels by 19.2% (P, .0001) vs placebo; subanalysis by statin efficacy revealed signif-
icant reductions vs placebo in the higher-efficacy andmedium-efficacy groups (24.6% and 17.2%, respec-
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636 Journal of Clinical Lipidology, Vol 10, No 3, June 2016CONCLUSION: Icosapent ethyl 4 g/day significantly reduced plasma ApoC-III levels in patients with
elevated TGs from the MARINE and ANCHOR studies.
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Icosapent ethyl (Vascepa; Amarin Pharma Inc.,
Bedminster, NJ, USA) is a high-purity prescription form
of the ethyl ester of the omega-3 fatty acid eicosapentae-
noic acid (EPA). It is approved by the US Food and Drug
Administration as an adjunct to diet to reduce triglyceride
(TG) levels in adult patients with severe hypertriglycer-
idemia (TG $500 mg/dL) at a dose of 4 g/day.1 The Multi-
Center, Placebo-Controlled, Randomized, Double-Blind,
12-Week Study With an Open-Label Extension (MARINE)
study examined the effects of icosapent ethyl on lipid pa-
rameters in patients with very high TG levels ($500 and
#2000 mg/dL), and the ANCHOR study examined the ef-
fects of icosapent ethyl on lipid parameters in statin-treated
patients with high TG levels ($200 and ,500 mg/dL).1–3
These studies demonstrated that icosapent ethyl 4 g/day
significantly reduced TG levels and improved other lipid
parameters including non–high-density lipoprotein choles-
terol (non-HDL-C), very-low-density lipoprotein choles-
terol (VLDL-C), very-low-density lipoprotein TG
(VLDL-TG) and apolipoprotein B (ApoB), without raising
low-density lipoprotein cholesterol (LDL-C).
Apolipoprotein C-III (ApoC-III) is a small protein that
resides on various lipoproteins and has emerged as an
important regulator of TG-rich lipoprotein (TRL) meta-
bolism and hepatic TG homeostasis.4–7 A primary role of
ApoC-III may be the reduction of TG clearance from
plasma via regulation of lipolysis through noncompetitive
inhibition of endothelial-bound lipoprotein lipase.4,5,8
Recent data suggest that ApoC-III may also be a regulator
of lipoprotein lipase-independent pathways of TRL
metabolism and clearance via receptor- and non–receptor-
mediated pathways.9,10 ApoC-III antagonizes ApoE-
induced and ApoB-induced lipoprotein clearance (i.e.,
impairs hepatic uptake), leading to accumulation of athero-
genic TRLs and their ApoC-III–containing remnants.6 In
addition to affecting TRL metabolism and clearance,
ApoC-III also appears to play a key role earlier in the
TRL cycle by stimulating hepatic assembly and secretion
of TG-rich VLDL.10 These mechanistic data are consistent
with the clinical findings of ApoC-III levels as an indepen-
dent predictor of angiographic coronary artery disease
progression.11 In addition, recent genomic studies have
identified loss-of-function mutations in ApoC-III, which
are associated with substantially lower TG levels and
reduced risk of cardiovascular disease (CVD).12,13 Thus,
the collective data support the strong association ofelevated plasma ApoC-III levels with hypertriglyceridemia
and CVD progression, and the potential for elevated plasma
ApoC-III levels to have a causal role in the development of
atherosclerosis.4–6,14
This post hoc analysis of the MARINE and ANCHOR
studies evaluated the effects of icosapent ethyl on plasma
ApoC-III levels and investigated correlations between
plasma levels of ApoC-III and those of TG and other
atherogenic parameters.Methods
Study design
Details of the designs and entry criteria for the MARINE
and ANCHOR studies are available in previous publica-
tions.2,3 Briefly, these were phase 3, randomized, placebo-
controlled, double-blind, parallel-group, multicenter trials
including patients aged .18 years with very high TG levels
($500 and #2000 mg/dL; MARINE study) or high TG
levels ($200 and ,500 mg/dL; ANCHOR study).2,3 Both
studies had a 12-week, double-blind treatment period
during which patients were randomized to receive either
icosapent ethyl 4 g/day, icosapent ethyl 2 g/day, or matched
placebo (light liquid paraffin). The MARINE study
permitted but did not require stable statin therapy with or
without ezetimibe.2 The ANCHOR study required patients
to be at high risk for CVD as defined by the National
Cholesterol Education Program Adult Treatment Panel III
guidelines15 and to be on a stable statin dose (atorvastatin,
rosuvastatin, or simvastatin with or without ezetimibe;
patients could not switch between statins).3 Before the start
of icosapent ethyl treatment, each of these studies had a
4-week to 6-week lead-in period of diet, lifestyle, and medi-
cation stabilization with washout of any prohibited lipid-
altering medications. The MARINE and ANCHOR studies
were conducted in accordance with the principles of Good
Clinical Practice and the Declaration of Helsinki. The
appropriate institutional review boards approved the proto-
col, and all patients provided written informed consent.
Assessments and measurements
This post hoc analysis measured total plasma ApoC-III
levels in the subset of all patients with available archived
plasma samples from MARINE and ANCHOR. The
measurements used an in vitro immunoturbidimetric
Ballantyne et al Effects of icosapent ethyl on plasma ApoC-III 637immunoassay using a Randox Daytona analyzer and
reagents from Sekisui Medical Corporation. The MARINE
and ANCHOR studies measured levels of TG, LDL-C,
non-HDL-C, VLDL-C, VLDL-TG, and Apo B as previ-
ously reported.2,16 Measurements are presented in mg/dL.
To convert from mg/dL to the International System unit
of mmol/L, multiply cholesterol by 0.0259 and multiply
TG by 0.0113. To convert ApoB and ApoC-III levels to
the SI unit of g/L, multiply by 0.01.
Plasma lipid parameter evaluations included patients
from the intent-to-treat (ITT) population, defined as all
randomized patients who had a baseline TG measurement,
received $1 dose of study drug, and had $1 postrandom-
ization efficacy measurement.
Statistical analysis
This post hoc analysis calculated medians and inter-
quartile ranges for each treatment group at baseline, week
12, and for percent changes from baseline for each lipid
parameter. This analysis also estimated median differences
in percent changes from baseline for each variable between
the icosapent ethyl and placebo groups with the Hodges–
Lehmann method. This analysis used the Wilcoxon
rank-sum test to calculate P values; subgroup analyses by
statin use (MARINE study), statin efficacy (lower, medium,
and higher; ANCHOR study), and median plasma ApoC-III
levels (both studies) were also conducted.
This post hoc analysis computed Pearson correlation
coefficients to assess the relationships between ApoC-III
and other lipid parameters. Associated P values are based
on the t-distribution with (n22) degrees of freedom. For
correlations at baseline, the analyses used pooled data
from the icosapent ethyl treatment and placebo groups.
Subanalyses included all statin-treated patients pooled
from both the MARINE and ANCHOR studies, and the
subset of patients from the MARINE study who did not
receive statins. No power calculations were performed. For
exploratory endpoints in the MARINE and ANCHOR
studies, 0.05 was the prespecified alpha for significance,
which was also used in all post hoc analyses, including
those reported here, which were exploratory in nature.Results
All randomized patients among treatment groups within
each study (Supplemental Table 1) had comparable base-
line demographics. In the MARINE study, 25% of patients
received statin therapy, whereas all patients in the
ANCHOR study received statin therapy based on study
entry criteria (93.2% received medium-efficacy or higher-
efficacy statin regimens). This analysis assessed plasma
ApoC-III levels in 148 and 612 patients from the MARINE
and ANCHOR studies, respectively. In each study, analysis
of median baseline TG, LDL-C, non-HDL-C, VLDL-C,
VLDL-TG, and ApoB revealed comparable levels acrosstreatment groups in the subset of patients with ApoC-III
measurements (Supplemental Table 1) and levels compara-
ble to those of the ITT population in each study.2,3 Analysis
of median baseline levels of ApoC-III also demonstrated
comparable results across treatment groups in each study
(Table 1).
Icosapent ethyl 4 g/day significantly reduced median
ApoC-III levels by 25.1% (P , .0001) in the MARINE
study and by 19.2% (P , .0001) in the ANCHOR study
vs placebo (Table 1, Figure 1). In a subanalysis of patients
from the MARINE study based on statin use, icosapent
ethyl 4 g/day significantly reduced median ApoC-III levels
by 26.1% vs placebo in patients who did not receive statin
therapy (n5 41; P5 .0001); in the small subset (n5 12) of
patients who received statin therapy, icosapent ethyl 4 g/day
reduced ApoC-III by 22.6% compared with placebo,
although this reduction approached but did not reach statis-
tical significance (P 5 .08), and there were differences in
baseline levels of ApoC-III between subset treatment
groups (Table 1). Subgroup analysis based on statin efficacy
regimens from the ANCHOR study showed that icosapent
ethyl 4 g/day, as compared with placebo, reduced median
ApoC-III levels by 24.6% in the higher-efficacy statin
subgroup (P , .0001; n 5 65) and by 17.2% in the
medium-efficacy statin subgroup (P , .0001; n 5 127);
in the lower-efficacy subgroup, the icosapent ethyl
4 g/day reduced ApoC-III by 18.4%, but this reduction
was not statistically significant and represents a small
number of patients (P 5 .3; n 5 16; Table 1; see table foot-
notes for statin efficacy subgroup definitions).
An analysis of the changes from baseline to 12 weeks
with icosapent ethyl 4 g/day vs placebo in median TG,
non-HDL-C, ApoB, LDL-C, and HDL-C levels and the
TG/HDL-C ratio in the subset of patients with ApoC-III
measurements from MARINE and ANCHOR produced
results similar to those of the full MARINE and ANCHOR
study cohorts (Table 2). In the MARINE study, median
baseline ApoC-III levels were higher compared to the
ANCHOR study (study-wide medians were 26.1 mg/dL
and 14.9 mg/dL, respectively). Changes in lipid parameters
closely linked to TRL metabolism revealed a general trend
toward greater reductions in the MARINE study than in the
ANCHOR study, with significant reductions observed
across both studies in ApoC-III (Table 1), TG, non-HDL-
C, and the ratio of TG/HDL-C (Table 2).
Lipid parameters were also assessed in patients stratified
into subgroups above or below each study-wide median
baseline ApoC-III level. In MARINE (Table 3) and
ANCHOR (Table 4), icosapent ethyl 4 g/d robustly reduced
ApoC-III, TG, non-HDL-C, and the TG/HDL-C ratio in the
subgroups of patients with ApoC-III levels above or below
the study’s baseline median of ApoC-III. In ANCHOR,
where all patients received statin treatment, those with
baseline ApoC-III levels above the median had greater
reductions vs placebo in TG and the TG/HDL-C ratio
than patients with baseline ApoC-III levels below the
median (Table 4).
Table 1 Change from baseline to week 12 in plasma ApoC-III levels in patients from the MARINE and ANCHOR studies (patients from ITT and statin subanalysis)
Study
Icosapent ethyl, 4 g/day Icosapent ethyl, 2 g/day Placebo
Icosapent ethyl,
4 g/day
Icosapent ethyl,
2 g/day
Baseline
End of
treatment Change, % Baseline
End of
treatment Change, % Baseline
End of
treatment Change, %
vs placebo,
%, P value
vs placebo,
%, P value
MARINE n 5 76 n 5 73 n 5 75
ITT* n 5 53 n 5 49 n 5 46
25.6 (11.6) 19.7 (10.5) 210.1 (27.1) 25.9 (11.1) 28.4 (12.0) 0.3 (29.9) 26.8 (17.3) 32.7 (14.6) 12.3 (41.5) 225.1, ,.0001 214.3, .0154
Statin use
Statin n 5 12 n 5 13 n 5 7
20.3 (12.9) 18.9 (12.5) 27.9 (28.1) 29.4 (10.8) 28.9 (4.6) 26.7 (33.2) 38.7 (13.5) 42.3 (21.1) 9.3 (68.9) 222.6, .0832 223.7, .0961
No statin n 5 41 n 5 36 n 5 39
25.6 (11.5) 19.7 (9.1) 211.6 (27.0) 25.1 (11.4) 23.5 (12.0) 1.3 (29.3) 26.1 (16.5) 30.5 (16.4) 12.6 (41.5) 226.1, .0001 212.6, .0543
ANCHOR n 5 226 n 5 234 n 5 227
ITT* n 5 208 n 5 203 n 5 201
15.2 (4.8) 13.7 (4.8) 29.4 (25.9) 14.8 (4.2) 14.8 (5.0) 20.6 (30.5) 14.8 (4.5) 16.2 (5.6) 10.9 (30.0) 219.2, ,.0001 28.5, .0008
Statin efficacy regimen†
Higher n 5 65 n 5 62 n 5 63
15.6 (4.4) 14.3 (5.0) 213.9 (25.1) 15.2 (4.4) 15.5 (6.4) 20.3 (34.8) 15.2 (4.3) 16.2 (6.5) 10.8 (34.0) 224.6, ,.0001 28.3, .0862
Medium n 5 127 n 5 128 n 5 124
14.9 (4.9) 13.4 (4.6) 27.3 (25.3) 14.5 (4.3) 14.6 (4.8) 20.9 (27.8) 14.7 (4.5) 16.2 (5.6) 10.6 (25.9) 217.2, ,.0001 28.5, .0038
Lower n 5 16 n 5 13 n 5 14
14.0 (4.1) 13.4 (3.7) 0.2 (26.8) 13.0 (2.6) 13.1 (2.3) 0.4 (30.3) 15.3 (8.5) 16.2 (4.0) 16.9 (58.3) 218.4, .2891 29.2, .7524
All baseline and end-of-treatment data are presented as mg/dL. Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges–Lehmann medians.
ApoC-III, apolipoprotein C-III; ITT, intent-to-treat; MARINE, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension.
*ITT population: all randomized patients who had a baseline triglyceride measurement, received $1 dose of study drug, and had $1 postrandomization efficacy measurement.
†Lower-efficacy statin regimens, simvastatin 5 to 10 mg; medium-efficacy statin regimens, rosuvastatin 5 to 10 mg, atorvastatin 10 to 20 mg, simvastatin 20 to 40 mg, simvastatin 10 to 20 mg plus
ezetimibe 5 to 10 mg; higher-efficacy statin regimens, rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg, simvastatin 80 mg, simvastatin 40 to 80 mg plus ezetimibe 5 to 10 mg.
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Figure 1 Median percentage change from baseline to week 12
vs placebo (Hodges–Lehmann medians) in ApoC-III plasma levels
in patients from the MARINE and ANCHOR studies. *P , .0001;
†P , .001; ‡P , .05. ApoC-III, apolipoprotein C-III; MARINE,
Multi-Center, Placebo-Controlled, Randomized, Double-Blind,
12-Week Study With an Open-Label Extension.
Ballantyne et al Effects of icosapent ethyl on plasma ApoC-III 639Finally, we performed correlation analyses between the
plasma levels of ApoC-III and associated lipids and
lipoproteins. Table 5 presents correlation analyses of
ApoC-III vs TG, non-HDL-C, ApoB, and the TG/HDL-C
ratio for MARINE and ANCHOR independently and for
the combined (pooled) MARINE and ANCHOR data set.
These correlation analyses revealed modest to robust statis-
tically significant correlations between baseline levels of
ApoC-III and baseline levels of TG (r 5 0.69–0.84, all
P , .0001), baseline levels of non-HDL-C (r 5 0.42–
0.65, all P # .0002), and baseline levels of the TG/HDL-
C ratio (r 5 0.49–0.70, all P # .0005). Weaker correlations
resulted between ApoC-III and ApoB, ranging from no
correlation within analyses of the MARINE data alone to
weak correlations within analyses including the ANCHOR
data (r 5 0.31–0.36, P , .0001). We also performed corre-
lation analyses for changes from baseline to 12 weeks for
each lipid/lipoprotein noted above vs changes from baseline
in ApoC-III within each treatment arm in both the
MARINE and ANCHOR data sets. These change-from-
baseline correlation coefficients (data not shown) displayed
similar trends to the baseline correlation analyses presented
herein.Discussion
ApoC-III plays a number of key roles in the synthesis,
secretion, and metabolism of TRL and appears to play
emerging and direct roles in vascular inflammation and
pancreatic beta-cell apoptosis.5,8,10,14,17,18 The potential
clinical benefits of ApoC-III reductions have not yet been
established in large prospective clinical intervention trials;however, a recent meta-analysis of 12 clinical studies found
significantly higher total and non-HDL ApoC-III levels in
patients with CVD than in controls.14 In addition, recent
genetic studies suggest a potential causal role for ApoC-
III in the development of vascular and coronary
disease.5,12,13,19 These genetic studies have associated
loss-of-function mutations in ApoC-III with cardioprotec-
tion, which has made ApoC-III a particularly compelling
potential target for therapy.12,13,20
The current post hoc analysis from the MARINE and
ANCHOR studies provides an exploratory examination of
the effects of icosapent ethyl on plasma ApoC-III levels in
patients with very high and high TG levels, respectively. In
addition to the previously reported effects of icosapent
ethyl in significantly reducing TG and ApoB without
increasing LDL-C,2,3 the present analysis showed that
icosapent ethyl 4 g/day significantly reduced plasma
ApoC-III levels, with greater reductions observed in the
MARINE study vs the ANCHOR study (25.1% vs 19.2%;
P , .0001 for both). Icosapent ethyl robustly reduced
ApoC-III in the MARINE and ANCHOR populations
across different median baseline levels of TG and ApoC-III.
Elevated plasma levels of ApoC-III can persist even on
statin therapy, and ApoC-III in VLDL and LDL was an
independent predictor of recurrent coronary events in
statin-treated patients in the CARE trial.21 As statins are
the cornerstone of managing dyslipidemia,4,22 additional
reduction of plasma ApoC-III with icosapent ethyl may
be of particular interest for statin-treated patients with
persistent elevations in ApoC-III and/or TG. It is notable
in the current analyses that icosapent ethyl reduced
ApoC-III in patients receiving stable statin therapy in
both the MARINE (TG $500 and #2000 mg/dL) and
ANCHOR ($200 and ,500 mg/dL) studies. In the
ANCHOR study, all patients took statins and those with
baseline ApoC-III levels above the study-wide median
had a more atherogenic lipid profile (i.e., higher TG,
non-HDL-C, and TG/HDL-C), along with more substantial
improvements in TG and the TG/HDL-C ratio with icosa-
pent ethyl 4 g/day, compared with patients with ApoC-III
below the median. In addition, icosapent ethyl 4 g/day
produced greater ApoC-III reductions among patients
receiving higher-efficacy statin regimens.
In agreement with prior research,23 patients with higher
baseline ApoC-III levels also had higher TG levels, as
demonstrated in comparing MARINE with ANCHOR.
Furthermore, the analysis demonstrated strong correlations
between baseline levels of ApoC-III and lipids/lipoproteins
related to TRLs (i.e., TG, TG/HDL-C ratio, non-HDL-
C).14,23–25 In contrast to TRL correlations, the analysis
revealed weaker correlations between ApoC-III and
ApoB: less robust correlations in ANCHOR (r 5 0.31–
0.36; P , .0001) and no correlations in patients with very
high TG levels from the MARINE study. The TG and
HDL Working Group of the Exome Sequencing Project
found a similarly weak correlation (r 5 0.36) between
plasma ApoC-III and ApoB concentration within the
Table 2 Change from baseline to week 12 in lipid parameters in patients from the MARINE and ANCHOR studies (patients from ITT populations with ApoC-III measurements)
Lipid parameter
Icosapent ethyl, 4 g/d Icosapent ethyl, 2 g/d Placebo
Icosapent
ethyl, 4 g/d
Icosapent
ethyl, 2 g/d
Baseline
End of
treatment Change, % Baseline
End of
treatment Change, % Baseline
End of
treatment Change, %
vs placebo,
%, P value
vs placebo,
%, P value
TG
MARINE n 5 53 n 5 49 n 5 46
679.5 (240.0) 504.0 (252.5) 227.2 (33.2) 664.5 (246.5) 619.0 (368.0) 27.0 (37.2) 713.5 (426.5) 881.3 (852.5) 10.1 (54.2) 237.0, ,.0001 221.0, .0074
ANCHOR n 5 208 n 5 203 n 5 201
267.0 (92.5) 220.8 (94.3) 217.5 (31.1) 254.0 (92.5) 243.0 (113.5) 27.4 (35.0) 259.0 (86.0) 269.5 (147.5) 6.2 (42.3) 221.9, ,.0001 211.4, .0003
Non-HDL-C
MARINE n 5 53 n 5 49 n 5 46
221.0 (80.0) 207.0 (78.0) 26.7 (18.9) 206.0 (68.0) 215.0 (74.0) 0.8 (17.2) 230.5 (95.0) 241.5 (134.0) 8.4 (36.8) 218.7, ,.0001 29.1, .0243
ANCHOR n 5 208 n 5 203 n 5 201
128.5 (33.5) 123.5 (39.0) 24.8 (22.1) 128.0 (33.0) 133.0 (39.0) 1.0 (24.6) 128.0 (34.0) 136.0 (42.0) 10.7 (27.1) 213.8, ,.0001 26.6, .0025
ApoB
MARINE n 5 52 n 5 49 n 5 46
123.5 (37.5) 117.0 (35.0) 22.4 (15.1) 119.0 (40.0) 119.0 (47.0) 1.0 (10.9) 115.0 (48.0) 115.5 (40.0) 4.8 (21.4) 26.2, .0499 22.9, .2802
ANCHOR n 5 206 n 5 202 n 5 199
91.5 (24.0) 89.5 (27.0) 22.2 (16.4) 91.0 (22.0) 95.0 (24.0) 1.9 (20.6) 91.0 (25.0) 98.0 (26.0) 7.1 (23.2) 29.4, ,.0001 24.2, .0126
LDL-C
MARINE n 5 53 n 5 49 n 5 46
86.0 (47.0) 90.0 (53.0) 26.2 (35.5) 84.0 (58.0) 94.0 (66.0) 1.9 (32.6) 83.5 (55.0) 76.5 (51.0) 23.7 (54.9) 22.0, .8224 6.1, .3775
ANCHOR n 5 207 n 5 202 n 5 200
82.0 (28.0) 83.0 (31.0) 2.2 (27.5) 82.5 (26.0) 87.0 (26.0) 3.0 (26.2) 84.0 (27.0) 89.0 (31.0) 8.8 (30.8) 25.6, .0165 23.5, .1189
HDL-C
MARINE n 5 53 n 5 49 n 5 46
26.0 (11.0) 27.0 (10.0) 0.0 (17.4) 28.0 (6.0) 29.0 (11.0) 0.0 (24.5) 27.0 (8.0) 27.0 (10.0) 0.0 (21.4) 23.2, .2863 20.3, .7199
ANCHOR n 5 208 n 5 203 n 5 201
37.0 (12.0) 37.0 (12.5) 22.2 (18.2) 38.0 (12.0) 38.0 (12.0) 2.2 (19.5) 38.0 (12.0) 39.0 (14.0) 4.8 (22.0) 24.7, .0017 21.9, .2145
TG/HDL-C ratio
MARINE n 5 53 n 5 49 n 5 46
23.6 (15.9) 21.0 (18.3) 225.1 (44.8) 24.5 (13.9) 20.9 (20.0) 26.3 (48.5) 26.1 (20.2) 34.4 (33.8) 10.3 (87.2) 234.7, .0005 220.1, .0448
ANCHOR n 5 208 n 5 203 n 5 201
7.2 (3.9) 5.7 (4.1) 216.3 (40.3) 6.6 (3.8) 6.3 (4.3) 28.1 (46.3) 6.6 (3.9) 6.7 (5.0) 1.7 (49.5) 216.4, ,.0001 28.7, .0131
All baseline and end-of-treatment data are presented as mg/dL. Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges–Lehmann medians.
ApoC-III, apolipoprotein C-III; ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
MARINE, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension; TG, triglyceride.
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Table 3 Change from baseline to week 12 in lipid parameters in patients from the MARINE study by study-wide median*
Lipid parameter
Icosapent ethyl, 4 g/day Icosapent ethyl, 2 g/day Placebo
Icosapent
ethyl, 4 g/day
Icosapent
ethyl 2 g/day
Baseline
End of
treatment Change, % Baseline
End of
treatment Change, % Baseline
End of
treatment Change, %
vs placebo,
%, P
vs placebo,
%, P
MARINE n 5 76 n 5 73 n 5 75
ApoC-III
$Study-wide
median
n 5 25 n 5 24 n 5 25
31.2 (6.6) 27.0 (11.6) 215.0 (28.3) 32.1 (6.8) 32.4 (8.5) 0.1 (26.4) 36.0 (10.3) 37.3 (16.3) 9.2 (36.9) 223.3, .0062 212.9, .0561
,Study-wide
median
n 5 28 n 5 25 n 5 21
19.1 (3.3) 18.0 (2.3) 26.3 (23.0) 20.7 (2.6) 20.8 (9.3) 1.9 (34.3) 19.0 (3.7) 25.2 (11.2) 16.3 (58.7) 229.3, .0008 219.0, .0672
TG
$Study-wide
median
n 5 25 n 5 24 n 5 25
684.0 (172.5) 602.0 (326.0) 226.4 (24.2) 825.5 (331.3) 843.8 (330.5) 0.6 (46.5) 867.0 (530.5) 1218 (755.0) 9.7 (34.6) 234.3, .0046 211.5, .1835
,Study-wide
median
n 5 28 n 5 25 n 5 21
630.3 (288.5) 429.3 (255.3) 228.2 (49.9) 578.5 (160.5) 508.5 (173.5) 210.4 (26.9) 543.5 (112.5) 651.0 (474.0) 17.9 (56.2) 242.2, .0002 229.5, .0144
Non-HDL-C
$Study-wide
median
n 5 25 n 5 24 n 5 25
246.0 (93.0) 220.0 (107.0) 26.7 (22.4) 232.5 (61.0) 219.5 (66.5) 20.4 (21.2) 264.0 (81.0) 297.0 (123.0) 10.0 (30.4) 217.6, .0093 29.9, .0767
,Study-wide
median
n 5 28 n 5 25 n 5 21
212.5 (62.5) 193.0 (70.5) 26.9 (16.7) 199.0 (53.0) 197.0 (48.0) 1.0 (16.9) 176.0 (74.0) 204.0 (58.0) 6.9 (46.2) 220.1, .0008 27.9, .1715
TG/HDL-C
$Study-wide
median
n 5 25 n 5 24 n 5 25
26.9 (15.0) 23.2 (15.7) 223.4 (44.8) 28.7 (23.1) 31.7 (26.9) 20.5 (53.1) 32.1 (18.9) 41.3 (32.9) 9.7 (72.0) 230.7, .0313 29.6, .4777
,Study-wide
median
n 5 28 n 5 25 n 5 21
22.1 (15.7) 17.2 (19.9) 226.5 (46.0) 19.7 (8.7) 19.0 (9.7) 215.1 (51.5) 20.6 (13.2) 21.7 (25.2) 22.6 (108.0) 238.9, .0066 230.1, .0579
All baseline and end-of-treatment data presented as mg/dL. Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges2Lehmann medians.
Baseline ApoC-III (patients from ITT population with ApoC-III measurements).
ApoC-III, apolipoprotein C-III; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; non-HDL-C, non-high-density lipoprotein cholesterol; MARINE, Multi-Center, Placebo-Controlled,
Randomized, Double-Blind, 12-Week Study With an Open-Label Extension; TG, triglyceride.
*Study-wide median 26.1 mg/dL.
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Table 4 Change from baseline to week 12 in lipid parameters in patients from the ANCHOR study by study-wide median*
Lipid parameter
Icosapent ethyl, 4 g/d Icosapent ethyl, 2 g/d Placebo
Icosapent ethyl,
4 g/d
Icosapent ethyl,
2 g/d
Baseline
End of
treatment Change, % Baseline
End of
treatment Change, % Baseline
End of
treatment Change, %
vs placebo,
%, P
vs placebo,
%, P
ANCHOR n 5 226 n 5 234 n 5 227
ApoC-III
$Study-wide
median
N 5 111 n 5 99 n 5 97
17.6 (3.4) 15.4 (4.5) 212.2 (22.2) 17.1 (3.0) 17.1 (5.5) 24.2 (26.7) 17.3 (3.1) 18.7 (4.8) 4.5 (30.7) 217.1, ,.0001 27.0, .0391
,Study-wide
median
N 5 97 n 5 104 n 5 104
12.9 (2.3) 11.8 (3.3) 22.1 (28.5) 12.8 (2.3) 13.0 (4.2) 4.4 (30.7) 12.7 (2.9) 14.1 (4.2) 16.7 (29.4) 218.7, ,.0001 29.6, .0064
TG
$Study-wide
median
n 5 111 n 5 99 n 5 97
309.0 (95.0) 248.0 (107.5) 220.7 (24.7) 284.0 (114.5) 270.5 (129.0) 28.7 (36.6) 299.5 (89.0) 335.0 (155.5) 3.6 (48.4) 225.6, ,.0001 211.4, .0166
,Study-wide
median
n 5 97 n 5 104 n 5 104
226.0 (49.5) 194.0 (74.0) 213.7 (36.9) 227.0 (64.3) 216.5 (86.8) 25.6 (32.5) 220.3 (49.5) 233.3 (82.8) 7.1 (38.6) 217.2, ,.0001 211.0, .0056
Non-HDL-C
$Study-wide
median
n 5 111 n 5 99 n 5 97
140.0 (36.0) 126.0 (41.0) 25.6 (17.3) 138.0 (34.0) 144.0 (48.0) 2.2 (27.9) 137.0 (36.0) 145.0 (49.0) 7.4 (29.5) 212.6, ,.0001 22.4, .4621
,Study-wide
median
n 5 97 n 5 104 n 5 104
117.0 (27.0) 120.0 (36.0) 0.0 (22.1) 121.0 (32.0) 124.0 (29.0) 0.9 (22.5) 117.0 (25.5) 134.5 (34.0) 13.4 (25.4) 214.0, ,.0001 210.3, .0003
TG/HDL-C ratio
$Study-wide
median
n 5 111 n 5 99 n 5 97
8.0 (4.8) 6.2 (4.4) 223.7 (36.1) 7.9 (5.3) 7.0 (5.2) 29.2 (47.0) 8.4 (4.2) 8.4 (6.2) 0.2 (61.7) 222.9, ,.0001 210.9, .0775
,Study-wide
median
n 5 97 n 5 104 n 5 104
6.2 (2.9) 5.5 (3.6) 28.5 (48.9) 6.2 (3.3) 5.6 (3.9) 27.9 (43.0) 5.7 (2.7) 5.8 (3.3) 2.6 (41.3) 28.6, .0629 26.7, .1169
All baseline and end-of-treatment data presented as mg/dL. Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges–Lehmann medians.
Baseline ApoC-III (patients from ITT population with ApoC-III measurements).
ApoC-III, apolipoprotein C-III; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride.
*Study-wide median 14.9 mg/dL.
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Ballantyne et al Effects of icosapent ethyl on plasma ApoC-III 643Framingham Heart Study Offspring cohort, whose subjects
had a mean 6 standard deviation baseline TG level of
129.8 6 110.8 mg/dL,13 whereas Klein et al24 found an
ApoC-III to ApoB correlation of r 5 0.50 (P , .0001) in
patients with normal TG levels (mean 6 standard devia-
tion, 82 6 57 mg/dL). Taken together, these correlation
values suggest that ApoC-III and ApoB levels may be
somewhat linked when TG levels are normal, but that this
association may weaken and eventually be lost as TG levels
increase. That is, for each particle containing a single
ApoB, the ApoC-III and TG content may increase, thus
weakening the correlation between ApoB and ApoC-III.8
The weak correlation between ApoC-III and ApoB may
depend on other factors, including the distribution of
ApoC-III in TRL and HDL fractions; ApoC-III is known
to shift between VLDL and HDL fractions via rapid
exchange.4
Other omega-3 fatty acid studies have also shown
reductions in ApoC-III levels.26–30 However, the present
findings are in contrast with previous studies, which found
no significant changes in ApoC-III after treatment with
EPA; this may be due to prior studies using lower doses,
shorter treatment durations, or patient populations with
lower baseline TG levels than in the present study.31,32
Despite the differences in study results, evidence seems
to suggest that ApoC-III secretion into the circulation
is strongly correlated with hypertriglyceridemia in hu-
mans.14,31,32 Some ApoC-III effects may be dependent on
or independent of lipoprotein lipase activity, and although
not measured in this study, assessment of lipoprotein lipase
may be important in elucidating the direct role of ApoC-III
in lowering plasma TG levels and may be an interesting
area for further investigations.9
The mechanisms whereby icosapent ethyl reduces
ApoC-III levels have not yet been fully elucidated. It is
possible that the observed reduction in ApoC-III levels is
simply a result of a reduction in the VLDL particles on
which it resides, either through reduced hepatic release
and/or increased plasma clearance. On the other hand, the
interrelated reductions in VLDL, TG, and ApoC-III may be
more complex. For example, icosapent ethyl therapy might
alter the hepatic levels and compartmentalization of free
fatty acids and TG and thereby regulate the assembly of
TG-rich and ApoC-III-rich VLDL. In addition, icosapent
ethyl may more directly reduce ApoC-III levels through
transcriptional regulation, which could then result in a
reduction in the assembly and secretion of TG-rich VLDL.
Therefore, multiple independent and interrelated mecha-
nisms may ultimately result in reduced hepatic release of
TG, VLDL, and ApoC-III.4,8,10,18,33–35 Once in plasma, a
decrease in ApoC-III would be expected to facilitate a
reduction in TG levels through a number of mechanisms,
including reduced inhibition of lipoprotein lipase and thus
increased lipoprotein lipase activity.18
Reductions in levels of TG, ApoC-III, and other
atherogenic lipids and lipoproteins, as well as the lack of
increase in LDL-C levels as compared with placebo
644 Journal of Clinical Lipidology, Vol 10, No 3, June 2016observed in prior analyses of the MARINE and ANCHOR
studies2,3 and in the present post hoc analysis, may be of
potential clinical benefit in the management of patients
with hypertriglyceridemia at increased coronary heart
disease risk. However, this remains to be determined as
the MARINE and ANCHOR studies did not assess cardio-
vascular outcomes. Recent results from the Improved
Reduction of Outcomes: Vytorin Efficacy International
Trial (IMPROVE-IT) have demonstrated that cardiovascu-
lar risk can be reduced by statin add-on therapy and that
incremental reductions in LDL-C led to incremental reduc-
tions in coronary artery disease events and underscore the
concept that lower LDL-C is better.36 The Japan EPA Lipid
Intervention Study (JELIS)37 (N 5 18,645) showed a 19%
reduction in the frequency of any major coronary event
with purified EPA-plus-statin therapy compared with a
statin-only control group, indicating a potential benefit of
purified EPA therapy in terms of CVD risk reduction
beyond LDL-C reduction. The ongoing Reduction of
Cardiovascular Events with EPA-Intervention Trial
(REDUCE-IT; NCT01492361), a randomized, double-
blind, placebo-controlled, parallel-group study, will assess
the effects of treatment with icosapent ethyl 4 g/day
compared with placebo on prevention of cardiovascular
events in high-risk statin-treated patients with hypertrigly-
ceridemia.38 The findings from REDUCE-IT will provide
important information on the impact of icosapent ethyl on
cardiovascular events in patients with high TG levels
despite statin treatment.Conclusions
ApoC-III plays a number of key roles in TRL
metabolism, and elevated ApoC-III levels are associated
with elevated TG levels and cardiovascular risk; therefore,
ApoC-III is an attractive putative target for cardiovascular
risk reduction, and therapies that can reduce ApoC-III levels
without increasing hepatic TG accumulation are particularly
attractive. This post hoc analysis of patients from the
MARINE and ANCHOR studies showed that an EPA-
only omega-3 ethyl ester (icosapent ethyl 4 g/day), alone or
in statin-treated patients, significantly reduced plasma
ApoC-III levels in patients with very high ($500 and
#2000 mg/dL; MARINE) or high ($200 and,500 mg/dL;
ANCHOR) TG levels, without increasing LDL-C levels.
Reductions in measures of TRL metabolism (ApoC-III, TG,
non-HDL-C, and the ratio of TG/HDL-C) appear to be
greater in subjects with higher baseline ApoC-III levels, as
observed when comparing the MARINE and ANCHOR
studies. These data suggest that the greatest clinical benefits
of EPA therapy may occur in the patients who are at the
highest cardiovascular risk, as signified by their ApoC-III
levels and associated atherogenic lipoprotein profile. The
MARINE and ANCHOR studies did not address the
cardiovascular benefit of icosapent ethyl therapy, but the
results of the ongoing REDUCE-IT study will help toestablish whether the improvements in patients’ atherogenic
risk profiles achieved during icosapent ethyl treatment are
associated with a reduction in cardiovascular events.Acknowledgment
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Supplemental Table 1 Baseline characteristics and baseline lipid parameters
Parameter Icosapent ethyl, 4 g/d Icosapent ethyl, 2 g/d Placebo
Baseline characteristics*
MARINE n 5 77 n 5 76 n 5 76
Age, mean (SD), y 51.9 (10.27) 53.4 (9.34) 53.4 (8.34)
Male, n (%) 59 (77) 58 (76) 58 (76)
Weight, mean (SD), kg 93.2 (18.27) 92.1 (15.57) 93.0 (16.92)
BMI, mean (SD), kg/m2 30.4 (4.29) 30.8 (4.24) 31.0 (4.25)
Diabetes, n (%) 22 (29) 20 (26) 21 (28)
ANCHOR n 5 233 n 5 236 n 5 233
Age, mean (SD), y 61.1 (10.03) 61.8 (9.42) 61.2 (10.05)
Male, n (%) 142 (61) 144 (61) 145 (62)
Weight, mean (SD), kg 94.5 (18.30) 95.5 (18.29) 97.0 (19.14)
BMI, mean (SD), kg/m2 32.7 (4.99) 32.9 (4.98) 33.0 (5.04)
Diabetes, n (%) 171 (73) 172 (73) 171 (73)
Baseline lipid parameters†,‡
MARINE n 5 53 n 5 49 n 5 46
TG (mg/dL) 679.5 (240.0), n 5 53 664.5 (246.5), n 5 49 713.5 (426.5), n 5 46
LDL-C (mg/dL) 86.0 (47.0), n 5 53 84.0 (58.0), n 5 49 83.5 (55.0), n 5 46
Non-HDL-C (mg/dL) 221.0 (80.0), n 5 53 206.0 (68.0), n 5 49 230.5 (95.0), n 5 46
VLDL-C (mg/dL) 122.0 (60.0), n 5 53 119.0 (54.0), n 5 49 132.5 (81.0), n 5 46
VLDL-TG (mg/dL) 521.0 (277.0), n 5 53 550.0 (315.0), n 5 49 563.0 (450.0), n 5 46
ApoB (mg/dL) 123.5 (37.5), n 5 52 119.0 (40.0), n 5 49 115.0 (48.0), n 5 46
ANCHOR n 5 208 n 5 203 n 5 201
TG (mg/dL) 267.0 (92.5), n 5 208 254.0 (92.5), n 5 203 259.0 (86.0), n 5 201
LDL-C (mg/dL) 82.0 (28.0), n 5 207 82.5 (26.0), n 5 202 84.0 (27.0), n 5 200
Non-HDL-C (mg/dL) 128.5 (33.5), n 5 208 128.0 (33.0), n 5 203 128.0 (34.0), n 5 201
VLDL-C (mg/dL) 44.0 (23.0), n 5 207 43.0 (21.0), n 5 202 41.5 (21.0), n 5 200
VLDL-TG (mg/dL) 190.0 (102.0), n 5 207 186.0 (87.0), n 5 202 184.0 (96.0), n 5 200
ApoB (mg/dL) 91.5 (24.0), n 5 206 91.0 (22.0), n 5 202 91.0 (25.0), n 5 199
ApoB, apolipoprotein B; ApoC-III, apolipoprotein C-III; BMI, body mass index; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol;
MARINE, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension; non-HDL-C, non-high-density
lipoprotein cholesterol; SD, standard deviation; TG, triglyceride; VLDL-C, very-low-density lipoprotein cholesterol; VLDL-TG, very-low-density lipoprotein
triglyceride.
*Patients from the randomized population.
†Data are presented as median (interquartile range) for baseline lipid parameter values.
‡Patients from the ITT populations with ApoC-III measurements.
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